Patients with a body mass index less than 25 kg/m2 prescribed a glucagon-like peptide-1 receptor agonist or glucagon-like peptide-1 receptor agonist/glucose-dependent insulinotropic polypeptide receptor agonist for type 2 diabetes mellitus within a single health system were included in this analysis. This evidence concerns the gene GIPR and type 2 diabetes mellitus.